long intergenic non-protein coding RNA 919Genealiases: []
Q-omics provides the consensus-scored LINC00919 profile across patient tissues and cancer cell-line models. LINC00919 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LINC00919 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, LINC00919 RNA expression shows 7,425 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, KIRC, and UVM as cancer lineages where LINC00919 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00919 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00919 survival associations across molecular data types. LINC00919 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00919 RNA expression–survival associations across cancer types. High LINC00919 expression shows unfavorable associations in CESC, STAD, UCEC and READ, but favorable associations in UVM and KICH. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for LINC00919 RNA expression.
This table summarizes LINC00919 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00919. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00919 shows lower tumor expression in KIRC and KIRP and higher tumor expression in KICH. The KIRC box plot shows higher LINC00919 RNA expression in normal versus tumor tissue (log2 FC = −0.279, t-test p < 0.001).
This table shows molecular features associated with LINC00919 in patient tissues and cancer cell lines. In patient samples, LINC00919 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
